Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.64 |
| ▸ | CA1 | P00915 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | FBP1 | P09467 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 4/20 | 0.50 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL752816 | 0.79 | CA1 (0.65) | CA2CA1MEN1PKMHTT | |
| SCHEMBL1364805 | 0.78 | CA1 (1.00) | CA2CA1GAAPKMHTT | |
| SCHEMBL6765743 | 0.78 | CA1 (0.58) | CA2CA1GAAMEN1PKM | |
| SCHEMBL5592750 | 0.75 | GAA (0.57) | CA2CA1GAAMEN1PKM | |
| SCHEMBL16059915 | 0.74 | CA1 (0.59) | CA2CA1MEN1PKMHTT | |
| SCHEMBL12419386 | 0.74 | CA2 (0.58) | CA2CA1PKMFBP1 | |
| SCHEMBL15315388 | 0.74 | CA2 (0.58) | CA2CA1FBP1MMP2LMNA | |
| SCHEMBL2181734 | 0.74 | CA1 (0.58) | CA2CA1GAAMEN1KMT2A | |
| SCHEMBL9344505 | 0.71 | ALDH1A1 (0.65) | PKMHTTMMP2LMNA | |
| SCHEMBL31315858 | 0.71 | ALDH1A1 (0.65) | PKMHTTMMP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107245023-B | A kind of selectivity deoxofluorination reagent and method | 中国科学院上海有机化学研究所 | 2019-08-16 | — | — | CN | disclosed |
| CN-107245023-A | A kind of selective deoxofluorination reagent and method | 中国科学院上海有机化学研究所 | 2017-10-13 | — | — | CN | disclosed |
| EP-2812332-B1 | METHODS FOR THE PREPARATION OF HIV ATTACHMENT INHIBITOR PIPERAZINE PRODRUG COMPOUND | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2017-08-09 | — | — | EP | disclosed |
| US-9403821-B2 | Methods for the preparation of HIV attachment inhibitor piperazine prodrug compound | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403821-B2 | Methods for the preparation of HIV attachment inhibitor piperazine prodrug compound | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-02 | — | — | US | disclosed |
| US-9394322-B2 | Methods for the preparation of HIV attachment inhibitor piperazine prodrug compound | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394322-B2 | Methods for the preparation of HIV attachment inhibitor piperazine prodrug compound | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-19 | — | — | US | disclosed |
| US-9376458-B2 | Methods for the preparation of HIV attachment inhibitor piperazine prodrug compound | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376458-B2 | Methods for the preparation of HIV attachment inhibitor piperazine prodrug compound | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160152644-A1 | METHODS FOR THE PREPARATION OF HIV ATTACHMENT INHIBITOR PIPERAZINE PRODRUG COMPOUND | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| WO-2013119625-A1 | METHODS FOR THE PREPARATION OF HIV ATTACHMENT INHIBITOR PIPERAZINE PRODRUG COMPOUND | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-15 | — | — | WO | disclosed |
| US-20130203992-A1 | METHODS FOR THE PREPARATION OF HIV ATTACHMENT INHIBITOR PIPERAZINE PRODRUG COMPOUND | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203992-A1 | METHODS FOR THE PREPARATION OF HIV ATTACHMENT INHIBITOR PIPERAZINE PRODRUG COMPOUND | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-08 | — | — | US | disclosed |
| US-20100204228-A1 | Aryl Sulfonamides Useful for Modulation of the Progesterone Receptor | WYETH LLC (US) | 2010-08-12 | — | — | US | disclosed |
| US-7723332-B2 | Aryl sulfonamides useful for modulation of the progesterone receptor | WYETH LLC (US) | 2010-05-25 | — | — | US | disclosed |
| EP-2137145-A2 | CYANOPYRROL SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | Wyeth (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008109055-A2 | CYANOPYRROLE SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221201-A1 | 4-(5-cyano-1-methyl-1H-pyrrol-2-yl)-N-methylbenzenesulfonamide; contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake | WYETH (US) | 2008-09-11 | — | — | US | disclosed |
| CN-100363348-C | PgD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARM INC (US) | 2008-01-23 | — | — | CN | disclosed |
| CN-1720047-A | PgD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARM INC (US) | 2006-01-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152644-A1 | METHODS FOR THE PREPARATION OF HIV ATTACHMENT INHIBITOR PIPERAZINE PRODRUG COMPOUND | FURIN, NAPA, PREP | CA2 4276/4885CA1 3943/4885GAA 1596/4885 |
| US-20130203992-A1 | METHODS FOR THE PREPARATION OF HIV ATTACHMENT INHIBITOR PIPERAZINE PRODRUG COMPOUND | FURIN, NAPA, PREP | CA2 4276/4885CA1 3943/4885GAA 1596/4885 |
| US-20100204228-A1 | Aryl Sulfonamides Useful for Modulation of the Progesterone Receptor | FSHR, GNRHR, CYP19A1 | CA2 2013/4885CA1 1620/4885GAA 4842/4885 |
| US-20080221201-A1 | 4-(5-cyano-1-methyl-1H-pyrrol-2-yl)-N-methylbenzenesulfonamide; contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake | PKD1, PKD2, SHBG | CA2 2127/4885CA1 1757/4885GAA 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.